<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''-->

Is there a regimen missing from this list?  Would you like to share a different dosage/schedule or an additional reference for a regimen?  Have you noticed an error?  Do you have an idea that will help the site grow to better meet your needs and the needs of many others?  You are [[How_to_contribute|invited to contribute to the site]].
{| class="wikitable" style="text-align:center; width:100%;"
!colspan="4" align="center" style="color:white; font-size:125%; background-color:#31a354"|'''Section editors'''
|-
|style="background-color:#F0F0F0; width:15%"|[[File:Shruti.jpg|frameless|upright=0.3|center]]
|style="width:35%"|<big>[[User:Shrutichaturvedi|Shruti Chaturvedi, MBBS, MSCI]]<br>Baltimore, MD</big><br>[https://www.linkedin.com/in/shruti-chaturvedi-bb83b126/ LinkedIn]
|style="background-color:#F0F0F0; width:15%"|[[File:Tillman_Benjamin-2.jpg|frameless|upright=0.3|center]]
|style="width:35%"|<big>[[User:Benjamintillman|Benjamin Tillman, MD]]<br>Nashville, TN</big>
|-
|}
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}

=All lines of therapy=

==BR {{#subobject:0fde6d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BR: '''<u>B</u>'''endamustine, '''<u>R</u>'''ituximab
===Regimen {{#subobject:47595c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/130/4/537.long Berentsen et al. 2017]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Bendamustine]] 90 mg/m<sup>2</sup> IV once per day on days 1 & 2

'''28-day cycle for 4 cycles'''

===References===
# Berentsen S, Randen U, Oksman M, Birgens H, Tvedt THA, Dalgaard J, Galteland E, Haukås E, Brudevold R, Sørbø JH, Næss IA, Malecka A, Tjønnfjord GE. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood. 2017 Jul 27;130(4):537-541. Epub 2017 May 22. [http://www.bloodjournal.org/content/130/4/537.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28533306 PubMed]

==Eculizumab monotherapy {{#subobject:08ef07|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:95a0a9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://ash.confex.com/ash/2015/webprogram/Paper79420.html Röth et al. 2015 (DECADE)]
|style="background-color:#ffffbe"|Phase II, <20 pts
|-
|}

''Eligible patients had symptomatic cold agglutinin-mediated hemolysis with a serum lactate dehydrogenase (LDH) level greater than or equal to 2 x upper limit of normal and a cold agglutinin titer greater than 1:64 at 4°C.''
====Therapy====
*[[Eculizumab (Soliris)]] 600 mg IV once per week for 4 weeks, then 900 mg IV once on week 5, then 900 mg IV every 2 weeks

====Supportive medications====
* Patients were vaccinated against ''Neisseria meningitidis'' or received "appropriate antibiotics" if vaccination occurred within 14 days of the first dose

'''26-week course'''

===References===
# '''Abstract:''' Alexander Röth, MD, Martin Bommer, MD, Andreas Hüttmann, MD, Dörte Herich-Terhürne, Nils Kuklik, PhD, Lenz Veronika, Hubert Schrezenmeier, MD and Ulrich Dührsen, MD. Complement Inhibition with Eculizumab in Patients with Cold Agglutinin Disease (CAD): Results from a Prospective Phase II Trial (DECADE Trial). ASH Annual Meeting 2015 Abstract 274 [https://ash.confex.com/ash/2015/webprogram/Paper79420.html link to abstract]

==FR {{#subobject:96c221|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FR: '''<u>F</u>'''ludarabine & '''<u>R</u>'''ituximab
===Regimen {{#subobject:645885|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/116/17/3180.long Berentsen et al. 2010]
|style="background-color:#91cf61"|Phase II
| style="background-color:#e0ecf4" |ORR: 76%
|-
|}

''Eligible patients had to be diagnosed with cold agglutinin disease and require therapy because of anemia, substantial cold-induced circulatory symptoms, or both.''
====Chemotherapy====
*[[Fludarabine (Fludara)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 5, 29 to 34, 57 to 61, 85 to 89
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days 1, 29, 57, 85

'''One course'''

===References===
# Berentsen S, Randen U, Vågan AM, Hjorth-Hansen H, Vik A, Dalgaard J, Jacobsen EM, Thoresen AS, Beiske K, Tjønnfjord GE. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood. 2010 Oct 28;116(17):3180-4. Epub 2010 Jul 15. [http://www.bloodjournal.org/content/116/17/3180.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20634373 PubMed]

==Rituximab monotherapy {{#subobject:65c6f1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:372fe5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/103/8/2925.long Berentsen et al. 2003]
|style="background-color:#91cf61"|Phase II
| style="background-color:#9ebcda" |ORR: 54%
|-
|[http://www.tandfonline.com/doi/full/10.1080/10428190500286481 Schöllkopf et al. 2006]
|style="background-color:#91cf61"|Phase II
| style="background-color:#8c96c6" |ORR: 45%
|-
|}

''Patients in '''Berentsen et al. 2003''' were required to have cold agglutinin disease, as defined by the combination of chronic hemolysis and a cold agglutinin titer of 1:64 or higher, and a typical pattern for the direct antiglobulin test (DAT).''
====Immunosuppressive therapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week

'''4-week course'''

===References===
# Berentsen S, Ulvestad E, Gjertsen BT, Hjorth-Hansen H, Langholm R, Knutsen H, Ghanima W, Shammas FV, Tjønnfjord GE. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004 Apr 15;103(8):2925-8. Epub 2003 Dec 30. [http://www.bloodjournal.org/content/103/8/2925.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15070665 PubMed]
# Schöllkopf C, Kjeldsen L, Bjerrum OW, Mourits-Andersen HT, Nielsen JL, Christensen BE, Jensen BA, Pedersen BB, Taaning EB, Klausen TW, Birgens H. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma. 2006 Feb;47(2):253-60. [http://www.tandfonline.com/doi/full/10.1080/10428190500286481 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16321854 PubMed]

[[Category:Cold agglutinin disease regimens]]
[[Category:Disease-specific pages]]
[[Category:Complementopathies]]
[[Category:Hemolytic disorders]]
